汪明振,邱成志,余外市,王春曉,郭延塔
(福建醫(yī)科大學(xué)附屬第二醫(yī)院 普外科,福建 泉州 362000)
GPP34激活結(jié)腸癌細(xì)胞Wnt信號(hào)通路促進(jìn)癌細(xì)胞增殖的研究*
汪明振,邱成志,余外市,王春曉,郭延塔
(福建醫(yī)科大學(xué)附屬第二醫(yī)院 普外科,福建 泉州 362000)
目的 探討人結(jié)腸癌細(xì)胞中高爾基相關(guān)蛋白34(GPP34)基因高表達(dá),激活經(jīng)典Wnt信號(hào)通路,促進(jìn)癌細(xì)胞增殖的機(jī)制。方法將SW620結(jié)腸癌細(xì)胞株分為4組:對(duì)照組、siRNA轉(zhuǎn)染組、Tricinbine組及TWS119組,分別培養(yǎng);逆轉(zhuǎn)錄聚合酶鏈反應(yīng)(RT-PCR)檢測(cè)結(jié)腸癌細(xì)胞轉(zhuǎn)染后的沉默效果;分別用Topflash報(bào)告基因活性法、噻唑藍(lán)(MTT)、流式細(xì)胞技術(shù)檢測(cè)各組癌細(xì)胞Wnt信號(hào)通路活性、生長(zhǎng)抑制率、細(xì)胞凋亡率;Western blot檢測(cè)各組結(jié)腸癌細(xì)胞中GPP34、β-catenin、pS9-糖原合酶激酶-3β(pS9-GSK-3β)蛋白的表達(dá)。結(jié)果轉(zhuǎn)染siRNA后,沉默結(jié)腸癌細(xì)胞GPP34表達(dá)效果佳;與對(duì)照組比較,各實(shí)驗(yàn)組癌細(xì)胞的生長(zhǎng)抑制率和凋亡率升高,且Wnt信號(hào)通路活性抑制。Western blot檢測(cè)結(jié)果顯示,siRNA-GPP34組GPP34蛋白表達(dá)下降,其余兩組GPP34蛋白表達(dá)比較,差異無(wú)統(tǒng)計(jì)學(xué)意義;siRNA轉(zhuǎn)染組、Tricinbine組和TWS119組的β-catenin和pS9-GSK3β蛋白表達(dá)降低。結(jié)論SW620結(jié)腸癌細(xì)胞中GPP34基因的高表達(dá)可通過(guò)激活經(jīng)典Wnt細(xì)胞信號(hào)通路,促進(jìn)癌細(xì)胞增殖并抑制其凋亡。
人結(jié)腸癌細(xì)胞;高爾基相關(guān)蛋白34;Wnt信號(hào)通路;增殖;糖原合酶激酶-3β;β-catenin
1.1 主要試劑
siRNA靶向GPP34(GCUUGCUUAAUCATGGTT AT)由上海吉瑪公司設(shè)計(jì)合成,逆轉(zhuǎn)錄酶購(gòu)于立陶宛Fermentus公司,SYBR Ex Taq試劑盒購(gòu)于日本TaKaRa公司。噻唑藍(lán)[3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide,MTT]、Tricinbine購(gòu)于美國(guó)Sigma公司,Annexin-V檢測(cè)試劑盒購(gòu)于美國(guó)Becton Dickinson公司,螢火蟲(chóng)熒光素酶底物及海腎熒光素酶底物購(gòu)于南京碧云天公司,TWS119購(gòu)于美國(guó)Santa cruz公司,兔抗人GPP34多克隆抗體購(gòu)于英國(guó)Abcam公司,兔抗人pS9-糖原合酶激酶-3β(pS9-glycogen synthasc kinase-3β,pS9-GSK-3β)單克隆抗體購(gòu)于美國(guó)Cell Signaling Technology公司,β-catenin、β-actin、辣根過(guò)氧化物酶標(biāo)記的羊抗兔抗體購(gòu)于美國(guó)Santa cruz公司。
1.2 細(xì)胞系及細(xì)胞培養(yǎng)
人結(jié)腸癌細(xì)胞株SW620購(gòu)于中科院上海細(xì)胞所。將人結(jié)腸癌細(xì)胞SW620培養(yǎng)在RPMI Medium 1640+10%胎牛血清(fetal calf serum,F(xiàn)BS)培養(yǎng)基中,置于37℃、5%二氧化碳CO2+95%空氣的飽和濕度環(huán)境的細(xì)胞培養(yǎng)箱進(jìn)行培養(yǎng)。
1.3 方法
1.3.1 實(shí)驗(yàn)分組 將結(jié)腸癌細(xì)胞株SW620進(jìn)行實(shí)驗(yàn)分組,接種細(xì)胞于6孔板,并將其分為4組:對(duì)照組 [等量磷酸鹽緩沖溶液(phosphate buffer saline,PBS)]、siRNA轉(zhuǎn)染組(轉(zhuǎn)染組采用脂質(zhì)體法,參照說(shuō)明書(shū)用50 nmol siRNA轉(zhuǎn)染SW620細(xì)胞)、Tricinbine組(加 Akt抑制劑 50 nmol)、TWS119組(加GSK-3β抑制劑50 nmol),繼續(xù)培養(yǎng)各組細(xì)胞。
1.3.2 逆轉(zhuǎn)錄聚合酶鏈反應(yīng)(reverse transcription polymerase chain reaction,RT-PCR)檢測(cè)轉(zhuǎn)染組沉默效果 用Trizol裂解法提取轉(zhuǎn)染組結(jié)腸癌細(xì)胞株總RNA,將RNA逆轉(zhuǎn)錄為cDNA,以甘油醛-3-磷酸脫氫酶(glyceraldehyde-3-phosphate dehydrogenase,GAPDH)作為內(nèi)參,進(jìn)行RT-PCR反應(yīng)。反應(yīng)條件:95℃預(yù)變性 20 s;95℃變性 10 s,60℃退火 20 s,72℃延伸20 s,共循環(huán)45次,在退火階段檢測(cè)熒光;熔解曲線條件為50℃預(yù)熱15 s,51℃升溫至99℃,每升高1℃停留5 s。GPP34正向引物:5'-AGGGCGA CTCCAAGGAAA-3';反向引物:5'-TGATGTGTAACC CTCGCG-3',產(chǎn)物長(zhǎng)度83 bp;聚合酶鏈反應(yīng)引物由上海吉瑪公司所設(shè)計(jì),使用GAPDH作為內(nèi)參,數(shù)據(jù)分析通過(guò)相對(duì)定量ΔCt法進(jìn)行。
當(dāng)學(xué)生面對(duì)問(wèn)題束手無(wú)策時(shí),教師要采取有效的方式,激活學(xué)生已有的數(shù)學(xué)活動(dòng)經(jīng)驗(yàn),使學(xué)生的學(xué)習(xí)基于經(jīng)驗(yàn)而又超越經(jīng)驗(yàn),完善數(shù)學(xué)活動(dòng)經(jīng)驗(yàn)。
1.3.3 Topflash報(bào)告基因活性法檢測(cè)Wnt信號(hào)通路活性 棄培養(yǎng)液,用PBS緩沖液洗1次,加入100 μl Harvest buffer作用10 min后裂解細(xì)胞,輕輕吸取其中40 μl置于離心管中,加入20 μl螢火蟲(chóng)熒光素酶底物或海腎熒光素酶底物。渦旋混勻后即刻用光度計(jì)檢測(cè)每孔中螢火蟲(chóng)熒光值及海腎熒光值,兩者的比值 [相對(duì)光單位值(relative luminescence units value,RLU)]即指示細(xì)胞內(nèi)Wnt信號(hào)通路中核內(nèi)轉(zhuǎn)錄因子 T 細(xì)胞因子(T cell factor,TCF)/淋巴樣增強(qiáng)因子(lymphoid enhancing factor,LEF)的激活水平。
1.3.4 MTT法檢測(cè)各組SW620結(jié)腸癌細(xì)胞的生長(zhǎng)抑制率 各組細(xì)胞經(jīng)胰酶消化后,接種于96孔板,加100 μl(1×105個(gè)細(xì)胞)/孔,貼壁培養(yǎng)24 h后,每組設(shè)4個(gè)復(fù)孔及對(duì)照孔,對(duì)照孔僅加入細(xì)胞不做處理。培養(yǎng) 48 h后,加5 mg/ml MTT 10 μl/孔培養(yǎng) 4 h,棄培養(yǎng)液。每孔加二甲基亞砜(Dimethyl Sulphoxide,DMSO)150 μl,避光振蕩混勻,結(jié)晶溶解后用酶標(biāo)儀檢測(cè)波長(zhǎng)490 nm吸光度A值。計(jì)算公式:癌細(xì)胞生長(zhǎng)抑制率=(1-處理組平均光密度(optical delnsity,OD)490值/對(duì)照組平均OD490值)×100%。
1.3.5 流式細(xì)胞技術(shù)Annexin V-FITC/PI法檢測(cè)各組細(xì)胞株的凋亡率 重懸各組細(xì)胞后取5~10萬(wàn)重懸的沉淀細(xì)胞,加入200 μl Annexin V-FITC結(jié)合液輕輕重懸細(xì)胞。加入10 μl碘化丙啶染色液,輕輕混勻。室溫避光孵育10~20 min,置于冰浴中。隨即進(jìn)行流式細(xì)胞儀檢測(cè),Annexin V-FITC為綠色熒光,碘化丙啶為紅色熒光。
1.3.6 Western blot檢測(cè)各組蛋白表達(dá) 收集處于對(duì)數(shù)生長(zhǎng)期的各組細(xì)胞進(jìn)行十二烷基硫酸鈉-聚丙烯酰胺(sodium dodecyl sulfate-polyacrylamide gelelectrophoresis,SDS-PAGE)電泳,然后濕轉(zhuǎn)至聚偏二氟乙烯(polyvinylidene fluoride,PVDF)膜,封閉60 min后分別加入一抗GPP34、pS9-GSK-3β、βcatenin、β-actin,4℃孵育過(guò)夜;三羥甲基氨基磷酸鹽緩沖溶液(phosphate buffer saline and tween 20,PBST)漂洗20 min/次,共3次;加入相應(yīng)的辣根過(guò)氧化物酶標(biāo)記的二抗溶液,室溫孵育1h;PBST漂洗10 min/次,共3次;增強(qiáng)化學(xué)發(fā)光法(enhanced chemiluminescence,ECL)試劑檢測(cè)。圖像應(yīng)用Image J軟件進(jìn)行灰度分析,目的蛋白表達(dá)的相對(duì)強(qiáng)度=目的條帶的灰度值/β-actin條帶的灰度值。
1.4 統(tǒng)計(jì)學(xué)方法
數(shù)據(jù)分析采用SPSS 19.0統(tǒng)計(jì)軟件,計(jì)量資料以均數(shù)±標(biāo)準(zhǔn)差(±s)表示,兩組間比較用獨(dú)立樣本t檢驗(yàn),多組間比較用單因素方差分析,各實(shí)驗(yàn)組與對(duì)照組比較用Dunnett-t檢驗(yàn),實(shí)驗(yàn)組兩兩比較用SNK-q檢驗(yàn),P<0.05為差異有統(tǒng)計(jì)學(xué)意義。
2.1 SW620結(jié)腸癌細(xì)胞siRNA轉(zhuǎn)染效果
SW620結(jié)腸癌細(xì)胞培養(yǎng)良好,對(duì)照組GPP34 mRNA的相對(duì)表達(dá)量為(1.000±0.092),siRNA轉(zhuǎn)染組GPP34 mRNA的相對(duì)表達(dá)量為(0.236±0.076),經(jīng)t檢驗(yàn),差異有統(tǒng)計(jì)學(xué)意義(t=5.57,P=0.005)。轉(zhuǎn)染組GPP34 mRNA的相對(duì)表達(dá)量低于對(duì)照組,轉(zhuǎn)染效果佳。見(jiàn)圖1。
圖1 SW620結(jié)腸癌細(xì)胞 (×100)
2.2 各組癌細(xì)胞Wnt信號(hào)通路的活性
對(duì)照組、siRNA轉(zhuǎn)染組、Tricinbine組及TWS119組SW620癌細(xì)胞的相對(duì)熒光素酶活性,即RLU值分別為(1.000±0.164) 與(0.342±0.061)、(0.359±0.125)和(0.365±0.155)。各組 RLU 值比較,經(jīng)單因素方差分析,差異有統(tǒng)計(jì)學(xué)意義(F=17.812,P=0.001)。各實(shí)驗(yàn)組分別與對(duì)照組比較,經(jīng)Dunnett-t檢驗(yàn),差異有統(tǒng)計(jì)學(xué)意義(P<0.05),各實(shí)驗(yàn)組RLU值低于對(duì)照組,表明抑制GSK-3β、Akt活性及沉默GPP34均可降低SW620結(jié)腸癌細(xì)胞的Wnt信號(hào)通道活性,且各實(shí)驗(yàn)組間RLU值兩兩比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05)。見(jiàn)圖 2。
圖2 各組SW620結(jié)腸癌細(xì)胞的Wnt信號(hào)通路活性比較(±s)
2.3 各組SW620結(jié)腸癌細(xì)胞生長(zhǎng)抑制率比較
MTT法檢測(cè)顯示,對(duì)照組、siRNA轉(zhuǎn)染組、Tricinbine組及TWS119組的癌細(xì)胞相對(duì)OD490值分別為 (1.000±0.147)、(0.401±0.010)、(0.434±0.116)和(0.487±0.077),siRNA 轉(zhuǎn)染組、Tricinbine組及TWS119組生長(zhǎng)抑制率分別為59.9%、56.6%和51.3%。各組生長(zhǎng)抑制率比較,經(jīng)單因素方差分析,差異有統(tǒng)計(jì)學(xué)意義(F=13.101,P=0.002)。各實(shí)驗(yàn)組分別與對(duì)照組比較,經(jīng)Dunnett-t檢驗(yàn),差異有統(tǒng)計(jì)學(xué)意義(P<0.05),各實(shí)驗(yàn)組生長(zhǎng)抑制率低于對(duì)照組,說(shuō)明抑制GSK-3β、Akt活性及沉默GPP34均可抑制SW620結(jié)腸癌細(xì)胞增殖。各實(shí)驗(yàn)組間兩兩比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05)。見(jiàn)圖3。
圖3 各組SW620結(jié)腸癌細(xì)胞相對(duì)OD490值比較(±s)
2.4 各組SW620結(jié)腸癌細(xì)胞凋亡率比較
流式細(xì)胞儀Annexin V法檢測(cè)各組細(xì)胞的凋亡率,對(duì)照組、siRNA轉(zhuǎn)染組、Tricinbine組及TWS119組SW620癌細(xì)胞的凋亡率分別為(1.680±0.576)%、(52.467±4.373)%、(46.167±5.293)%和(50.167±6.506)%。各組凋亡率比較,經(jīng)單因素方差分析,差異有統(tǒng)計(jì)學(xué)意義(F=77.610,P=0.000)。各實(shí)驗(yàn)組分別與對(duì)照組比較,經(jīng)Dunnett-t檢驗(yàn),差異有統(tǒng)計(jì)學(xué)意義(P<0.05),各實(shí)驗(yàn)組癌細(xì)胞的凋亡率較對(duì)照組提高,提示抑制GSK-3β、Akt活性及沉默GPP34均可促進(jìn)癌細(xì)胞凋亡。且各實(shí)驗(yàn)組間兩兩比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05)。見(jiàn)圖 4、5。
圖4 各組SW620結(jié)腸癌細(xì)胞的凋亡情況
圖5 各組SW620結(jié)腸癌細(xì)胞凋亡率比較
2.5 β-catenin、pS9-GSK-3β及 GPP34蛋白的表達(dá)
各組的 GPP34、pS9-GSK-3β、β-catenin蛋白相對(duì)表達(dá)量比較,經(jīng)單因素方差分析,差異有統(tǒng)計(jì)學(xué)意義(F=125.479、22.787 和 132.135,均P=0.000)。各實(shí)驗(yàn)組蛋白相對(duì)表達(dá)量與對(duì)照組比較,經(jīng)Dunnett-t檢驗(yàn)結(jié)果:①在GPP34蛋白檢測(cè)中,siRNA-GPP34組與對(duì)照組比較,差異有統(tǒng)計(jì)學(xué)意義(P<0.05),siRNA轉(zhuǎn)染組的GPP34蛋白相對(duì)表達(dá)量低于對(duì)照組;其余兩組與對(duì)照組比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05),沉默效果良好;②3個(gè)實(shí)驗(yàn)組中β-catenin和pS9-GSK-3β蛋白相對(duì)表達(dá)量分別與對(duì)照組比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P<0.05)。各實(shí)驗(yàn)組間蛋白相對(duì)表達(dá)量?jī)蓛杀容^,經(jīng)SNK-q檢驗(yàn)結(jié)果:①GPP34蛋白:Tricinbine組、TWS119組與siRNA-GPP34組比較,差異有統(tǒng)計(jì)學(xué)意義(P<0.05),而 Tricinbine組與 TWS119組比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05);②β-catenin蛋白:siRNA-GPP34組、Tricinbine組與TWS119組比較,差異有統(tǒng)計(jì)學(xué)意義(P<0.05),而 siRNA-GPP34組與Tricinbine組比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05);③pS9-GSK-3β蛋白表達(dá)在各實(shí)驗(yàn)組間比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05)。見(jiàn)附表和圖 6、7。
附表 各組蛋白的相對(duì)表達(dá)量比較 (±s)
附表 各組蛋白的相對(duì)表達(dá)量比較 (±s)
注:t1、P1:對(duì)照組 vs siRNA 轉(zhuǎn)染組;t2、P2:對(duì)照組 vs Tricinbine 組;t3、P3:對(duì)照組 vs TWS119 組;q1:Tricinbine組 vs TWS119 組;q2:siRNA轉(zhuǎn)染組 vs TWS119組;q3:siRNA轉(zhuǎn)染組 vs Tricinbine組
組別β-catenin對(duì)照組 1.000±0.015 1.000±0.194 1.000±0.088 siRNA轉(zhuǎn)染組 0.260±0.008 0.280±0.043 0.182±0.010 Tricinbine組 0.906±0.006 0.208±0.065 0.192±0.073 TWS119組 0.983±0.078 0.371±0.160 0.362±0.018 t1值 73.138 2.272 0.316P1值 0.000 0.053 0.762 t2值 6.272 6.703 4.324P2值 0.003 0.003 0.012 t3值 16.006 12.210 12.313P3值 0.000 0.000 0.000 q1值 1.491 1.948 32.553 q2值 14.151 1.080 32.842 q3值 12.655 0.872 0.289 GPP34pS9-GSK-3β
圖6 GPP34、pS9-GSK-3β及β-catenin蛋白的表達(dá)
圖7 各實(shí)驗(yàn)組GPP34、pS9-GSK-3β及β-catenin蛋白相對(duì)表達(dá)量比較
近來(lái)研究表明,GPP34基因可促進(jìn)癌細(xì)胞的生長(zhǎng)、增殖并抑制凋亡,是一種新的原癌基因[6-7]。在胃癌[8]、肝癌等[9]多種癌組織中存在GPP34表達(dá)明顯上調(diào),且與細(xì)胞分化差、淋巴結(jié)轉(zhuǎn)移、分期晚、惡性程度高呈正相關(guān)。目前研究表明,GPP34高表達(dá)可通過(guò)雷帕霉素靶蛋白的復(fù)合體(mammalian target of rapamycin complex,mTORC)1 和 mTORC2底物磷酸化激活mTOR信號(hào)通路,加速細(xì)胞增殖分裂[7],但是否存在激活其它細(xì)胞內(nèi)信號(hào)通路,未見(jiàn)文獻(xiàn)報(bào)道。因此,在筆者前期研究基礎(chǔ)上,采用沉默GPP34基因方法進(jìn)一步探討GPP34高表達(dá)激活經(jīng)典Wnt信號(hào)通路的機(jī)制。
經(jīng)典Wnt信號(hào)通路激活后可抑制降解復(fù)合體(由GSK-3β、結(jié)直腸腺瘤性息肉蛋白、軸蛋白等蛋白組成)中關(guān)鍵活性成分GSK-3β的磷酸化,使βcatenin避免被泛素蛋白酶體識(shí)別和降解,并與轉(zhuǎn)錄因子TCF/LEF結(jié)合而導(dǎo)致細(xì)胞增殖的異常,促進(jìn)腫瘤的發(fā)生、發(fā)展[10-11]。已有研究證實(shí),結(jié)腸癌等腫瘤細(xì)胞中Wnt信號(hào)通路存在過(guò)度激活,且與腫瘤的發(fā)生、發(fā)展關(guān)系密切,可能成為結(jié)腸癌的防治的新途徑[12-13]。本實(shí)驗(yàn)首次顯示沉默GPP34基因表達(dá)可降低經(jīng)典Wnt信號(hào)通路活性,提示GPP34的高表達(dá)可激活SW620結(jié)腸癌細(xì)胞經(jīng)典Wnt信號(hào)通路,促進(jìn)細(xì)胞增殖并抑制凋亡。
GPP34高表達(dá)可增強(qiáng)表皮生長(zhǎng)因子引起的核糖體S6激酶表達(dá)水平升高,同時(shí)可通過(guò)Ser473磷酸化激活A(yù)kt,Akt激活后的作用底物包括mTOR和GSK-3β等,GSK-3β是經(jīng)典Wnt信號(hào)通路的關(guān)鍵調(diào)節(jié)因子,其磷酸化后可通過(guò)對(duì)β-catenin的影響參與細(xì)胞增殖、凋亡的調(diào)控[14]。本實(shí)驗(yàn)顯示,沉默GPP34基因表達(dá)、阻斷Akt或GSK-3β位點(diǎn)后β-catenin和pS9-GSK-3β蛋白表達(dá)均降低,SW620結(jié)腸癌細(xì)胞增殖和Wnt信號(hào)通路活性受到抑制,細(xì)胞凋亡增加,提示GPP34的高表達(dá)可上調(diào)pS9-GSK-3β和βcatenin蛋白表達(dá),因此筆者推斷GPP34高表達(dá)可通過(guò)Akt/GSK-3β激活Wnt信號(hào)通路,促進(jìn)結(jié)腸癌細(xì)胞的增殖。
綜上所述,SW620結(jié)腸癌細(xì)胞中GPP34基因的高表達(dá)可激活經(jīng)典Wnt細(xì)胞信號(hào)通路促進(jìn)癌細(xì)胞增殖,抑制凋亡,其機(jī)制可能是通過(guò)激活A(yù)kt,進(jìn)一步通過(guò)GSK-3β介導(dǎo)Wnt細(xì)胞信號(hào)通路的激活。GPP34可作為結(jié)腸癌靶向治療的潛在新靶點(diǎn)。
[1]王飛,李建國(guó),吳巧斌,等.P21活化激酶6在結(jié)腸癌組織中的表達(dá)及其意義[J].中國(guó)現(xiàn)代醫(yī)學(xué)雜志,2015,28:7-11.
[2]SIERSEMA P D.Colorectal cancer awareness issue[J].Endoscopy,2015,47(3):185.
[3]邱成志,余外市,王春曉,等.高爾基磷酸化蛋白3在結(jié)直腸癌組織中的表達(dá)及其臨床意義[J].中華實(shí)驗(yàn)外科雜志,2013,30(8):461-463.
[4]余外市,邱成志,王春曉,等.結(jié)直腸癌組織中Golph3的表達(dá)與細(xì)胞凋亡的相關(guān)性[J].中國(guó)腫瘤臨床,2013,40(18):1094-1097.
[5]周志平,邱成志,余外市,等.結(jié)直腸癌組織中高爾基磷酸化蛋白3表達(dá)與Wnt信號(hào)通路的關(guān)系[J].中華實(shí)驗(yàn)外科雜志,2013,30(12):2709-2710.
[6]SCOTT K L,CHIN L.Signaling from the Golgi:mechanisms and models for Golgi phosphoprotein 3-mediated oncogenesis[J].Clin Cancer Res,2010,16(8):2229-2234.
[7]SCOTT K L,KABBARAH O,LIANG M C,et al.GOLPH3 modulatesi mTOR signalling and rapamycin sensitivity in cancer[J].Nature,2009,459:1085-1090.
[8]PENG J Z,FANG Y,TAO Y,et al.Mechanisms of GOLPH3 associated with the progression of gastric cancer:a preliminarystudy[J].PLoS One,2014,9(10):DOI:10.1371/journal.pone.0107362.
[9]DAI T,ZHANG D,CAI M,et al.Golgi phosphoprotein 3(GOLPH3)promotes hepatocellular carcinoma cell aggressiveness by activating the NF-kB pathway[J].The Journal of Pathology(J Pathol),2015,235(3):490-501.
[10]PANDURANGAN A K.Potential targets for prevention of colorectal cancer:a focus on PI3K/Akt/mTOR and Wnt pathways[J].Asian Pac J Cancer Prev,2013,14(4):2201-2205.
[11]XU L,ZHANG L,HU C,etal.WNT pathwayinhibitor pyrvinium pamoate inhibits the self-renewal and metastasis of breast cancer stem cells[J].Int J Oncol,2016,48(3):1175-1186.
[12]AMADO N G,PREDES D,MORENO M M,et al.Flavonoids and Wnt/β-catenin signaling:potential role in colorectal cancer therapies[J].Int J Mol Sci,2014,15(7):12094-12106.
[13]田笑笑,杜浩,鄭玉峰,等.Smad4基因轉(zhuǎn)染對(duì)結(jié)腸癌細(xì)胞中Wnt/β-catenin信號(hào)通路的影響[J].中國(guó)現(xiàn)代醫(yī)學(xué),2013,23(33):11-16.
[14]FREESE J L,PINO D,PLEASURE S J.Wnt signaling in development and disease[J].Neurobiol Dis,2010,38(2):148-153.
(童穎丹 編輯)
GPP34 promotes colon cancer cell proliferation through activation of Wnt signaling pathway*
Ming-zhen Wang,Cheng-zhi Qiu,Wai-shi Yu,Chun-xiao Wang,Yan-ta Guo
(Department of General Surgery,the Second Affiliated Hospital of Fujian Medical University,Quanzhou,Fujian 362000,China)
ObjectiveTo investigate the mechanism of high-expression of Golgi-associated protein of 34(GPP34)gene in activation of Wnt signaling pathway to promote colon cancer cell proliferation.Methods Colon cancer cell lines were divided into four groups:control group,siRNA transfection group,the group of added inhibitor of Akt/Protein Kinase B (Tricinbine group),and the group of added inhibitor of GSK-3β(TWS119 group).The cells were cultured respectively.The silencing effect ofGPP34gene was detected by RT-PCR.The proliferation and apoptosis of the cancer cells in all groups were detected by MTT and flow cytometry respectively.Topflash reporter gene activity assay was used to detect the activity of Wnt signaling pathway in the cancer cells of each group.The expressions of GPP34,β-catenin and pS9-GSK-3β proteins in the cancer cells of all groups were detected by Western blot.ResultsThe expression level ofGPP34mRNA in the transfection group was significantly lower than that in the control group (P<0.05).Compared to the control group,the growth inhibition rate and the apoptosis rate were significantly increased(P<0.05),and the activity of Wnt signaling pathway was significantly inhibited in each experimental group (P<0.05).However,the growth inhibition rate,the apoptosis rate and the activity of Wnt signaling pathway showed no significant differences among the experimental groups(P>0.05).Compared to the control group,GPP34 protein expressionsignificantly decreased in the siRNA transfection group (P<0.05),while that in the other two experimental groups had no significant difference(P>0.05);β-catenin and pS9-GSK-3β protein expressions were significantly decreased in the three experimental groups(P<0.05).ConclusionsHigh-expression of GPP34 can activate the classical Wnt signaling pathway to promote proliferation and inhibit apoptosis of SW620 colon cancer cells.
human colorectal cancer cell line;GPP34;Wnt signaling pathway;proliferation;glycogen synthase kinase-3β;β-catenin
R735.35
A
10.3969/j.issn.1005-8982.2017.12.003
1005-8982(2017)12-0015-06
2016-08-18
福建省自然科學(xué)基金(No:2015J01438);福建醫(yī)科大學(xué)校教授基金(No:JS14028)
邱成志,E-mail:qchengzhi@sohu.com